Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties.

Fioravanti J, González I, Medina-Echeverz J, Larrea E, Ardaiz N, González-Aseguinolaza G, Prieto J, Berraondo P.

Hepatology. 2011 Jun;53(6):1864-73. doi: 10.1002/hep.24306. Epub 2011 May 2.

PMID:
21425312
2.

The fusion protein of IFN-α and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism.

Fioravanti J, Medina-Echeverz J, Ardaiz N, Gomar C, Parra-Guillén ZP, Prieto J, Berraondo P.

J Immunol. 2012 Apr 15;188(8):3988-92. doi: 10.4049/jimmunol.1101598. Epub 2012 Mar 14.

3.

Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I.

Berraondo P, Di Scala M, Korolowicz K, Thampi LM, Otano I, Suarez L, Fioravanti J, Aranda F, Ardaiz N, Yang J, Kallakury BV, Tucker RD, Vasquez M, Menne S, Prieto J, González-Aseguinolaza G.

J Hepatol. 2015 Aug;63(2):329-36. doi: 10.1016/j.jhep.2015.02.048. Epub 2015 Mar 12.

4.

Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies.

Ji C, Sastry KS, Tiefenthaler G, Cano J, Tang T, Ho ZZ, Teoh D, Bohini S, Chen A, Sankuratri S, Macary PA, Kennedy P, Ma H, Ries S, Klumpp K, Kopetzki E, Bertoletti A.

Hepatology. 2012 Dec;56(6):2027-38. doi: 10.1002/hep.25875. Epub 2012 Jul 12.

PMID:
22684948
5.

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.

Xuan C, Steward KK, Timmerman JM, Morrison SL.

Blood. 2010 Apr 8;115(14):2864-71. doi: 10.1182/blood-2009-10-250555. Epub 2010 Feb 4.

6.

Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.

Echeverria I, Pereboev A, Silva L, Zabaleta A, Riezu-Boj JI, Bes M, Cubero M, Borras-Cuesta F, Lasarte JJ, Esteban JI, Prieto J, Sarobe P.

Hepatology. 2011 Jul;54(1):28-37. doi: 10.1002/hep.24325. Epub 2011 May 14.

PMID:
21452282
7.

Anti-hepatitis B virus activity and mechanisms of recombinant human serum albumin-interferon-alpha-2b fusion protein in vitro and in vivo.

Bingfa X, Qinglin F, Hui H, Canjun W, Wei W, Lihua S.

Pharmacology. 2009;83(6):323-32. doi: 10.1159/000215588. Epub 2009 Apr 29.

PMID:
19407486
8.

Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.

Zhu H, Butera M, Nelson DR, Liu C.

Virol J. 2005 Sep 7;2:80.

9.

[Hepatitis C, interferon a and depression: main physiopathologic hypothesis].

Vignau J, Karila L, Costisella O, Canva V.

Encephale. 2005 May-Jun;31(3):349-57. Review. French.

PMID:
16142050
11.

Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.

Trinh KR, Vasuthasawat A, Steward KK, Yamada RE, Timmerman JM, Morrison SL.

J Immunother. 2013 Jun;36(5):305-18. doi: 10.1097/CJI.0b013e3182993eb9.

12.
13.
14.

Target specific hyaluronic acid-interferon alpha conjugate for the treatment of hepatitis C virus infection.

Yang JA, Park K, Jung H, Kim H, Hong SW, Yoon SK, Hahn SK.

Biomaterials. 2011 Nov;32(33):8722-9. doi: 10.1016/j.biomaterials.2011.07.088. Epub 2011 Aug 26.

PMID:
21872329
15.

Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.

Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gúrpide A, Prieto J, Pardo J, Berraondo P, Melero I.

Cancer Res. 2013 Jan 1;73(1):139-49. doi: 10.1158/0008-5472.CAN-12-2660. Epub 2012 Nov 13.

16.

Hyaluronic acid-gold nanoparticle/interferon α complex for targeted treatment of hepatitis C virus infection.

Lee MY, Yang JA, Jung HS, Beack S, Choi JE, Hur W, Koo H, Kim K, Yoon SK, Hahn SK.

ACS Nano. 2012 Nov 27;6(11):9522-31. doi: 10.1021/nn302538y. Epub 2012 Oct 26.

PMID:
23092111
17.

Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV.

Flores MV, Hickling TP, Sreckovic S, Fidock MD, Horscroft N, Katragadda M, Savic B, Rawal J, Delpuech-Adams OE, Robas N, Corey T, Nelms L, Lawton M, Marcek J, Stubbs M, Westby M, Ciaramella G.

Antivir Ther. 2012;17(5):869-81. doi: 10.3851/IMP2099. Epub 2012 Apr 13. Erratum in: Antivir Ther.2012;17(5):939.

PMID:
22505586
18.

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.

Rossi EA, Rossi DL, Cardillo TM, Stein R, Goldenberg DM, Chang CH.

Blood. 2011 Aug 18;118(7):1877-84. doi: 10.1182/blood-2011-03-343145. Epub 2011 Jun 16.

19.

Persistence of high density lipoprotein particles in obese mice lacking apolipoprotein A-I.

Gruen ML, Plummer MR, Zhang W, Posey KA, Linton MF, Fazio S, Hasty AH.

J Lipid Res. 2005 Sep;46(9):2007-14. Epub 2005 Jul 1.

20.

Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo.

Lim R, Knight B, Patel K, McHutchison JG, Yeoh GC, Olynyk JK.

Hepatology. 2006 May;43(5):1074-83.

PMID:
16628647
Items per page

Supplemental Content

Write to the Help Desk